This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Archived

This page has been archived on the Web.

Health product recall

Riva-Quetiapine 300 mg

Starting date:
May 17, 2013
Posting date:
June 4, 2013
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type I
Source of recall:
Health Canada
Issue:
Product Safety, Contamination
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-33887

Recalled products

  1. Riva-Quetiapine 300 mg

Reason

Potential cross-contamination of trace amounts of Clindamycin in Quetiapine Active Pharmaceutical Ingredient during the manufacturing process.

Depth of distribution

Wholesalers and pharmacies in Quebec, Ontario, and British-Columbia

Affected products

A. Riva-Quetiapine 300 mg

DIN, NPN, DIN-HIM
DIN 02316730
Dosage form
  • Tablet
Strength
  • 300 mg / tablet
Lot or serial number

Bottle size: 100 tabs

  • P3902
  • P5600
  • P5757
  • P5278
  • C0454
  • C0455
Companies
Recalling Firm
Laboratoire Riva Inc.
660 Industrial Blvd.
Blainville
J7C 3V4
Quebec
CANADA
Marketing Authorization Holder
Laboratoire Riva Inc.
660 Industrial Blvd.
Blainville
J7C 3V4
Quebec
CANADA

Date modified: